For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Nexstar Pharmaceuticals, Inc.

USPTO Granted Patents = 131

CIPO Patents = 1

Trademarks = 1

Forward Citations = 7,543

Loading Chart...

Loading Chart...

85 inventors (with patents filed for the assignee):

Larry M Gold (94 out of 191 patents)

Sumedha D Jayasena (20 out of 27 patents)

Nebojsa Janjic (18 out of 70 patents)

4. Bruce Eaton (15 out of 36 patents)

5. Kirk B Jensen (11 out of 14 patents)

6. Craig Tuerk (10 out of 18 patents)

7. Diane Tasset (10 out of 10 patents)

8. Karl Y Hostetler (8 out of 73 patents)

9. Andrew Stephens (8 out of 11 patents)

10. Gary P Kirschenheuter (7 out of 19 patents)

11. Jill P Adler-Moore (7 out of 10 patents)

12. Drew Smith (6 out of 9 patents)

13. Su-Ming Chiang (6 out of 10 patents)

14. Nikos C Pagratis (6 out of 14 patents)

15. Chi Tu (5 out of 8 patents)

Core Competencies:

Nucleic Acid Ligands

Oligonucleotide Ligands

Antiviral Therapies

Hepatitis B Treatment

High Affinity Ligands

VEGF Complexes

Tumor Targeting

DNA Polymerase Inhibitors

Systematic Evolution of Ligands

Therapeutic Agents

Flow Cytometry

Liposome Preparation

131 patents: Sort by Forward Citations

1. 6252060 - Antiviral liponucleosides: treatment of hepatitis B (2001-06-26),

2. 6229002 - Platelet derived growth factor (PDGF) nucleic acid ligand complexes (2001-05-08),

3. 6207816 - High affinity oligonucleotide ligands to growth factors (2001-03-27),

4. 6184364 - High affinity nucleic acid ligands containing modified nucleotides (2001-02-06),

5. 6183967 - Nucleic acid ligand inhibitors to DNA polymerases (2001-02-06),

6. 6177557 - High affinity ligands of basic fibroblast growth factor and thrombin (2001-01-23),

7. 6177555 - Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction (2001-01-23),

8. 6171795 - Nucleic acid ligands to CD40ligand (2001-01-09),

9. 6168778 - Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes (2001-01-02),

10. 6147204 - Nucleic acid ligand complexes (2000-11-14),

11. 6143882 - Urea nucleosides as therapeutic and diagnostic agents (2000-11-07),

12. 6140490 - High affinity nucleic acid ligands of complement system proteins (2000-10-31),

13. 6127119 - Nucleic acid ligands of tissue target (2000-10-03),

14. 6124449 - High affinity TGF.beta. nucleic acid ligands and inhibitors (2000-09-26),

15. 6120800 - Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting (2000-09-19),

Nexstar Pharmaceuticals, Inc., based in Boulder, Colorado, specializes in the development of innovative nucleic acid ligands and oligonucleotide therapies. The company focuses on advancing antiviral treatments, particularly for Hepatitis B, leveraging high affinity ligands and VEGF complexes for targeted tumor therapies. With a commitment to addressing unmet medical needs, Nexstar is at the forefront of research in DNA polymerase inhibitors and other cutting-edge therapeutic modalities, aiming to improve patient outcomes through precision medicine.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

131 Patents

#9 in Boulder, CO

#60 in Colorado

#2,959 in US

#6,133 in the World

Boulder, CO, United States of America

Nexstar Pharmaceuticals, Inc.

Forward Citations = 7,543

85 inventors:

Larry M Gold (94 out of 191 patents)

Sumedha D Jayasena (20 out of 27 patents)

Nebojsa Janjic (18 out of 70 patents)

4. Bruce Eaton (15 out of 36 patents)

5. Kirk B Jensen (11 out of 14 patents)

Please report any incorrect information to [email protected]

Loading…